Open peer commentary regarding Aβ immunization and CNS inflammation by Pasinetti et al.

Neurobiology of Aging

Volumn 23, Issue 5, 2002, Pages 671-674

  Das, Pritam ^a   Golde, Todd E ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID; AMYLOID BETA PROTEIN; ANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE;

AGING; ALZHEIMER DISEASE; ANTIBODY TITER; BEHAVIOR; CELL ACTIVATION; CLINICAL TRIAL; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; ENCEPHALITIS; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; MICROGLIA; NEUROPROTECTION; NONHUMAN; NOTE; PHAGOCYTOSIS; PRIORITY JOURNAL; SENILE PLAQUE;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ENCEPHALITIS; HUMANS; IMMUNIZATION;

EID: 0036752545     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(02)00031-3     Document Type: Note

References (11)

1. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T.et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400:1999;173-177.
2. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H.et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6:2000;916-919.
3. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., Holtzman D. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 98:2001;8850-8855.
4. Bacskai B.J., Kajdasz S.T., Christie R.H., Carter C., Games D., Seubert P.et al. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. 7:2001;369-372.
5. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D.et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 408:2000;979-982.
6. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J.et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408:2000;982-985.
7. Das P., Murphy M.P., Younkin L.H., Younkin S.G., Golde T.E. Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol. Aging. 22:2001;721-727.
8. Lemere C.A., Maron R., Spooner E.T., Grenfell T.J., Mori C., Desai R.et al. Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann. New York Acad. Sci. 920:2000;328-331.
9. Monsonego A., Maron R., Zota V., Selkoe D.J., Weiner H.L. Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 98:2001;10273-10278.
10. McGeer P.L., Schulzer M., McGeer E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 47:1996;425-432.
11. Weggen S., Eriksen J., Das P., Sagi S.A., Wang R., Pietrzik C.U.et al. Selective NSAIDs preferentially lower amyloidogenic Aβ42 by a COX-independent mechanism. Nature. 414:2001;212-216.